Login to Your Account



Potential $390M in Milestones

Micromet, Bayer Schering Sign Preclinical BiTE Antibody Deal

By Jennifer Boggs


Tuesday, January 13, 2009
The Bethesda, Md.-based biotech is no stranger to such preclinical deals, having partnered its early MT203 program with Nycomed A/S in a potential €125 million deal and its D93 antibody with Tracon Pharmaceuticals Inc. for up-front and milestone payments that could top $100 million. (See BioWorld Today, March 19, 2007, and May 25, 2007.) (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription